Experimental drug aims to halt liver failure in cirrhosis patients
NCT ID NCT07694297
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests whether adding the drug NTZ to standard care can help people with liver cirrhosis who experience a sudden worsening (acute decompensation) or have developed acute-on-chronic liver failure. The trial enrolls adults with cirrhosis from any cause who have had a recent acute decline. Researchers are primarily checking if NTZ is safe and tolerable in this setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NTZ (nitazoxanide)
- What this could lead to
- If successful, this could offer a new treatment option to stabilize patients with acute liver decompensation or early liver failure, potentially reducing progression and improving survival.
- What could go wrong
- This is an early-phase trial with only 16 participants, so results may not apply broadly. NTZ may cause side effects or fail to show benefit over standard care alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATION OF LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••